Abstract:The Fc gamma receptor (FcγR), a member of the immunoglobulin superfamily, binds the IgG Fc segment of antibodies and is mainly expressed on the surface of immune cell. The FcγR binds to the Fc region of an antibody that is attached to target cells, transmitting an activation or inhibition signal to the FcγR expressing cells, resulting in various biological responses and functions. Many therapeutic antibodies are developed based on the engineering of the Fc region to fine-tune the FcγR mediated effects. There are four subtypes of mouse FcγRs, including Fcgr1, Fcgr2b, Fcgr3, and Fcgr4. In contrast, human FcγRs consist of at least seven members, including FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B. Additionally, the expression pattern of even the orthologous FcγR genes varies between humans and mice. e.g., the distribution of mouse FCGR3 and FCGR2. Therefore, animals harboring the murine FcγRs are not ideal models for the accurate preclinical evaluation of human therapeutic antibodies. To address this problem, we established an FcγRs fully humanized mouse model by injecting an engineered human bacterial artificial chromosome construct carrying all seven human FcγR genes into mouse zygotes. The transgene carriers were mated with another strain in which all mouse FcγR genes were knocked out to establish the colony. Unlike the endogenous mouse FcγR genes expression profiles, the transgenic human FcγR genes regulated under the control of the human control elements retain the human expression pattern. For example, the transgenic human FCGR3A was observed on mouse NK cells and macrophages, whereas the FCGR3B was detected on mouse neutrophils only, which were consistent with their expression patterns in humans. Antibody-dependent cellular cytotoxicity (ADCC) experiment indicated that a human therapeutic antibody could direct NK cells derived from the FcγRs fully-humanized mice to kill target tumor cells. Moreover, a significant anti-tumor effect could also be achieved by an ADCC based human antibody in tumor-bearing FcγRs humanized mice. Taken together, the FcγR gene fully-humanized model established in this study demonstrates a human FcγR expression pattern and functionality, thus providing a valuable tool for accurate preclinical evaluation of human therapeutic antibodies. Citation Format: Mingkun Zhang, Cunxiang Ju, Ying Li, Yunlong Jiang, Weiwei Yu, Shuai Li, Hongyan Sun, Zhiying Li, Jing Zhao, Xiang Gao. Development of an Fc gamma receptor fully-humanized mouse model to support the accurate preclinical study of therapeutic antibodies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2584.

Humanization of an Anti-Human Tnf-Alpha Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling

Abstract 2584: Development of an Fc gamma receptor fully-humanized mouse model to support the accurate preclinical study of therapeutic antibodies

Novel human single chain antibody design based on the functional epitope of TNF

Humanization Design of Antibody HAb18 Based on Variable Domain Resurfacing

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

Reconstruction and Analysis of A Human Small Molecular Antibody to Tumor Necrosis Factor Alpha

Antibody Humanization By A Single Cycle Of Cdr-Grafting

Identification of Binding Epitope of a Monoclonal Antibody (Z12) Against Human TNF-α Using Computer Modeling and Deletion Mutant Technique

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Optimization and Modification of Anti-Rhtnf-α Single Chain Variable Fragment Antibody: Effective in Vitro Affinity Maturation and Functional Expression of Chimeric Fab.

[Development of an Anti-Rtnf-alpha Chimeric Antibody].

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

Structure-based humanization of a therapeutic antibody for multiple myeloma

A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies

Engineering and Characterization of a Humanized Antibody Targeting TNF-α and RANKL.

A humanized monovalent CD3 antibody which can activate homologous complement

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

Antibody humanization—the Influence of the antibody framework on the CDR-H3 loop ensemble in solution

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α